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The mechanisms by which p53 suppresses tumor growth remain ill defined. In this issue of Cell
Reports, Timofeev et al. (2013) and Valente et al. (2013) reveal context-dependent contributions
of p53-dependent apoptosis to its tumor-suppressive function.The fact that p53 suppresses tumor
growth is well established, but the mech-
anism by which it does so is still up in the
air. After three decades of research, only
this much is certain: p53 stops cancers
by binding to DNA and activating tran-
scription. The requirement for its DNA
binding activity is amply demonstrated
by the fact that nearly all mutations found
in cancers cluster within its DNA binding
domain. Additionally, the requirement for
at least one of its two N-terminal transac-
tivation domains (TADs) was elegantly
demonstrated by mouse knockin experi-
ments (Brady et al., 2011). However, a
key question in the field remains unan-
swered: Which p53 target genes mediate
its tumor-suppressive function? In this
issue of Cell Reports, two papers, from
the Strasser and Stiewe teams respec-
tively (Valente et al., 2013; Timofeev
et al., 2013), bring us closer to the answer,
which is not a simple one.
At first glance, the titles of the two
papers seem to state opposite conclu-
sions regarding the role of apoptosis in
p53-mediated tumor suppression, but
a second look reveals little conflict,
because p53 probably employs context-
dependent mechanisms to prevent
tumorigenesis. Upon activation, p53
drives transcription of genes acting in
diverse cellular processes including apo-
ptosis, cell-cycle arrest, senescence,
DNA repair, autophagy, angiogenesis,
glucose metabolism, and control of reac-
tive oxygen species (Riley et al., 2008).
Early work pointed to apoptosis, cell-
cycle arrest, and senescence as the key
p53 effector pathways delivering tumor
suppression. However, more recentwork demonstrated that p53 mutants un-
able to transactivate key genes in these
pathways retained tumor suppression in
mice (Brady et al., 2011; Li et al., 2012).
The controversy is most evident around
the role of apoptosis. p53 is a direct trans-
activator of many genes acting in the
intrinsic and extrinsic branches of the
apoptotic machinery, including the pore
protein BAX, the BH3-only proteins
PUMA and NOXA, and the death receptor
DR5 (Riley et al., 2008). PUMA is an inhib-
itor of BCL2-like survival factors that is
required for p53-dependent apoptosis in
response to diverse stimuli. In mouse
models of MYC-driven B cell lymphomas,
BCL2 overexpression bypasses the
requirement for p53 inactivation during
lymphomagenesis (Schmitt et al., 2002),
and deletion of DR5, BAX, PUMA, or
NOXA accelerates disease progression
(Eischen et al., 2001; Finnberg et al.,
2008; Michalak et al., 2009). Collectively,
these data support the conclusion that
apoptosis is a primary effector of p53-
dependent tumor suppression. Or is it?
p53/ mice are cancer prone, with
>90% of animals dying of T cell lym-
phomas. Using knockin strategies, the
Attardi and Gu teams recently generated
two distinct p53 mutants, each defective
in transactivation of Puma, Noxa, and
the cell-cycle inhibitor p21 (Cdkn1a)
(Brady et al., 2011; Li et al., 2012). They
demonstrated that these p53 mutant
mice remain protected from thymic lym-
phoma, thus concluding that increased
expression of these genes is dispensable
for suppression of this malignancy. How-
ever, it remained formally possible that
these three key p53 target genes contrib-Cell Reports 3, May 30, 2013 ª2013 The Authouted to tumor suppression when induced
at low levels or when activated by other
factors. To address this issue, the
Strasser group generated the triple-
knockout mouse p21/Puma/Noxa/
(Valente et al., 2013). Cells from these
animals showed defects in DNA-damage-
induced cell-cycle arrest and senes-
cence, and their thymocytes failed to
undergo apoptosis upon DNA damage.
Strikingly, none of the triple-knockout
mice showed spontaneous tumor forma-
tion up to 500 days, whereas the
entire p53
/
cohort succumbed before
250 days. So what is p53 doing to protect
these mice from thymic lymphomas? The
authors note that the kinetics of DNA
repair upon acute DNA damage was
significantly delayed in p53/ dermal
fibroblasts relative to wild-type cells;
however, there was no delay in the
triple-knockout cohorts. Furthermore,
they observed that several p53 target
genes involved in DNA repair were nor-
mally induced in the triple-knockout ani-
mals and suggested that the ability of
p53 to orchestrate DNA repair may
protect these animals from tumor devel-
opment. Overall, the Strasser team rein-
forces the conclusion of the Attardi and
Gu groups that apoptosis and cell-cycle
arrest are dispensable modules of the
p53 network during tumor suppression
of spontaneous thymic lymphoma.
Previous work from the Stiewe team
demonstrated that p53 mutants that fail
to bind DNA in a cooperative fashion
cannot transactivate apoptotic genes
in human cells, including PUMA and
NOXA, while retaining their ability to trans-
activate p21 (Schlereth et al., 2010). Inrs 1335Open access under CC BY-NC-ND license.
order to test the role of cooperative DNA
binding in vivo, the Stiewe group created
mouse strains expressing ‘‘cooperativity
mutant’’ p53 alleles (p53RR/RR) (Timofeev
et al., 2013). As expected, p53RR/RR cells
fail to transactivate Puma and Noxa and
show impaired apoptosis uponDNA dam-
age and MYC overexpression. Interest-
ingly, p53RR/RR mice are tumor prone
and develop hematological malignancies,
angiosarcomas, and carcinomas, sug-
gesting that apoptosis is important for
tumor suppression in this context. How-
ever, given that neither Puma/Noxa/
double-knockout (Michalak et al.,
2008) nor p21/Puma/Noxa/ triple-
knockout animals (Valente et al., 2013)
show such tumor propensity, we must
conclude that the p53RR/RR phenotype is
due to defects in p53 target gene transac-
tivation beyond that of Puma and Noxa,
perhaps in other branches of the apo-
ptotic pathway. Importantly, p53RR/RR
mice live longer than p53/ mice and
show fewer and more delayed appear-
ance of thymic lymphomas. Thus, in
agreement with the work from the Attardi,
Gu, and Strasser teams, the Stiewe group
concludes that even in the absence of
apoptosis p53 can maintain some barrier
against T cell lymphomas (Timofeev
et al., 2013). However, in contrast to
Strasser, the Stiewe group proposes
that p53RR/RR mutants suppress these
tumors via p53 target genes that mediate
antioxidant functions and inhibit glycol-
ysis, thus minimizing oxidative DNA
damage, rather than through mainte-
nance of DNA repair.1336 Cell Reports 3, May 30, 2013 ª2013 ThThe detailed analysis of p53RR/RR mice
reinforced the importance of context
with regards to p53 apoptotic functions.
In addition to the increased incidence of
diverse spontaneous tumors in p53RR/RR
mice, Stiewe and colleagues observed
that p53RR/RRmutants could not suppress
the growth of Ras/E1A-driven fibrosar-
coma xenografts or MYC-driven B cell
lymphomas and concluded that p53-
dependent apoptosis remains an ob-
stacle for cancer progression in the
context of oncogene-driven tumorigen-
esis (Timofeev et al., 2013).
The current status of the field indicates
that p53 employs context-dependent
mechanisms of tumor suppression, with
varying roles for the apoptotic program.
What do these new studies suggest about
p53 function in human tumors? p53
mutants that fail to effectively induce
apoptosis clearly retain other activities
that keep unchallenged mice free of
thymic lymphomas. But humans have a
much longer lifespan and undergo more
environmental insults than a laboratory
mouse, increasing the chances of
acquiring an oncogenic driver mutation.
Furthermore, thymic lymphomas are rare
in the human population, and >85% of
cancer deaths are caused by carcinomas,
in which p53 mutations usually occur late
during tumor development, after onco-
gene hyperactivation. As the field puts
emphasis on novel p53 target genes and
pathways outside of apoptosis and arrest,
wemust remainmindful that context is the
hallmark of biological processes, and that
different branches of the p53 network wille Authors Open access under CC BY-NC-ND license.contribute differentially to its tumor-sup-
pressive function across diverse tumor
types.
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